FDA / 2025

EGRIFTA WR prescribing information

EGRIFTA WR prescribing information — U.S. FDA (2025), cited in PeptideAgent's Tesamorelin evidence record.

Open original source

SOURCE METADATA

What this record represents.

Publisher
U.S. FDA
Evidence type
FDA
Publication year
2025
Source ID
fda-egrifta-label

WHERE THIS IS CITED

Connected evidence records.

TesamorelinPeptide analog · Growth Hormone